CIK 0001826457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Monte Rosa Therapeutics, Inc.
Sign in to watch- Ticker
- GLUE
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 617-949-2643
- Business address
- 321 HARRISON AVENUE, SUITE 900, BOSTON, MA, 02118
- Former names
- Monte Rosa Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $137
- in 1 filing
Net −$137. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 35 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-01 | Warmuth Markus President & CEO | Sale 10b5-1 | −5,467 | $18.92 | $103K | 600,004 |
| 2026-04-14 | Warmuth Markus President & CEO | Sale | −8,000 | $17.64 | $141K | 605,471 |
| 2026-04-09 | Nickson Philip Chief Business & Legal Officer | Sale | −5,845 | $17.69 | $103K | 55,000 |
| 2026-04-06 | Bowen Matthew Principal Accounting Officer | Grant or award | +4,300 | 25,904 | ||
| 2026-04-06 | Bowen Matthew Principal Accounting Officer | Grant or award · Stock Option (Right to Buy) | +19,500 | 19,500 | ||
| 2026-03-04 | Dunn Edmund Principal Accounting Officer | Sale | −139 | $17.96 | $2K | 22,554 |
| 2026-03-02 | Warmuth Markus President & CEO | Sale 10b5-1 | −5,466 | $17.92 | $98K | 613,471 |
| 2026-03-02 | Dunn Edmund Principal Accounting Officer | Option exercise | +536 | $13.41 | $7K | 23,229 |
| 2026-03-02 | Dunn Edmund Principal Accounting Officer | Sale | −536 | $17.50 | $9K | 22,693 |
| 2026-03-02 | Dunn Edmund Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) | −536 | 0 | ||
| 2026-02-27 | Dunn Edmund Principal Accounting Officer | Option exercise | +25,164 | $13.41 | $337K | 47,857 |
| 2026-02-27 | Dunn Edmund Principal Accounting Officer | Sale | −25,164 | $18.10 | $456K | 22,693 |
| 2026-02-27 | Dunn Edmund Principal Accounting Officer | Option exercise · Stock Option (Right to Buy) | −25,164 | 536 | ||
| 2026-02-23 | Janku Filip Chief Medical Officer | Sale | −9,189 | $19.50 | $179K | 65,837 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −3,707 | $23.24 | $86K | 620,696 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −1,450 | $23.88 | $35K | 619,246 |
| 2026-01-07 | Warmuth Markus President & CEO | Sale 10b5-1 | −309 | $24.57 | $8K | 618,937 |
| 2026-01-05 | Nickson Philip Chief Business & Legal Officer | Sale | −3,155 | $15.17 | $48K | 60,845 |
| 2026-01-05 | Champoux Jennifer Chief Operating Officer | Sale | −2,629 | $15.17 | $40K | 62,371 |
| 2026-01-05 | Dunn Edmund Principal Accounting Officer | Sale | −1,039 | $15.17 | $16K | 22,693 |
Page 4 of 9 · 174 trades